紫杉醇与西罗莫司洗脱支架在糖尿病患者冠状动脉介入治疗中的疗效与安全性的Meta分析

王辉波; 杨简; 杨俊; 丁家望; 刘晓雯; 曾萍; 黄纬凌; 杨英

doi:10.13201/j.issn.1001-1439.2016.10.005

紫杉醇与西罗莫司洗脱支架在糖尿病患者冠状动脉介入治疗中的疗效与安全性的Meta分析

- 三峡大学第一临床学院心血管病研究所(湖北宜昌, 443000)

详细信息

通讯作者: 杨俊,E-mail:yangjun@ctgu.edu.cn

中图分类号: R541.4

收稿日期: 2015-05-13

Safety and efficacy of paclitaxel-eluting stents versus sirolimus-eluting stents in diabetes patients undergoing percutaneous coronary intervention:A Meta analysis

- Institute of Cardiovascular Diseases, the First College of Clinical Medical Sciences, China Three Gorges University, Yichang, 443000, China

More Information

Corresponding author: YANG Jun, E-mail: yangjun@ctgu.edu.cn

Received Date: 13 May 2015

摘要

摘要: 目的:比较紫杉醇洗脱支架(PES)与西罗莫司洗脱支架(SES)在糖尿病患者冠状动脉介入治疗中的有效性和安全性。方法:通过Medline、EMBASE、Cochrane library数据库检索2016年5月之前所有相关英文临床随机对照试验(RCTs)。两名评价者利用Jadad评分量表独立评价纳入RCTs的质量并提取资料,评估全因死亡率、支架血栓形成(ST)率及靶病变血运重建(TLR)、靶血管血运重建(TVR)、心肌梗死(MI)、主要不良心脏事件(MACE)发生率,并用Review Manager 5.3软件进行统计分析。结果:最终分析数据来源于9个RCT试验。SES组与PES组全因死亡率、ST率以及MI发生率无统计学差异,但SES组TLR、TVR率以及MACE发生率明显优于PES组(均P<0.05)。结论:从目前临床研究看,对于糖尿病患者,SES的安全性和有效性优于PES。
- 紫杉醇 /
- 西罗莫司 /
- 药物洗脱支架 /
- 糖尿病 /
- Meta分析
Abstract: Objective:To investigate the safety and efficacy of paclitaxel-eluting stents(PES)versus sirolimuseluting stents(SES)in diabetes patients undergoing percutaneous coronary intervention(PCI).Method:We systematically searched the literature through the MEDLINE,Cochrane library,and EMBASE database.Quality assessments were evaluated with Jadad quality scale.Outcomes content the rate of all-cause mortality,stent thrombosis(ST),target lesion revascularization(TLR),target vessel revascularization(TVR),myocardial infarction(MI),major adverse cardiac events(MACE).All statistical analyses were performed using Review Manager 5.3.Result:Nine RCTs satisfying the inclusion criteria were finally analyzed.There was no significant difference in allcause mortality,ST and MI.Whereas there was a significant decrease of TLR,TVR,MACE.Conclusion:From the current clinical research,the safety and efficacy of SES is better than PES in diabetes patients undergoing PCI.
- paclitaxel /
- sirolimus /
- eluting stent /
- diabetes mellitus /
- Meta-analysis

HTML全文

参考文献(19)

[1]	ROLLINI F,ANGIOLILLO D J,ROLLINI F,et al.Acute coronary syndromes:Applying practice guidelines and defining the unmet need in clinical practice[J].Am J Cardiol,2015,115:1A-2A.
[2]	TOWNSEND N,NICHOLS M,SCARBOROUGH P,et al.Cardiovascular disease in Europe-epidemiological update 2015[J].Eur Heart J,2015,36:2673-2674.
[3]	OSTADAL B.The past,the present and the future of experimental research on myocardial ischemia and protection[J].Pharmacol Rep,2009,61:3-12.
[4]	NAGANUMA T,CHIEFFO A,MELIGA E,et al.Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the delta registry:a multicenter registry evaluating percutaneous corona[J].JACC Cardiovas Interv,2014,7:354-361.
[5]	BAVRY A A,PARK K.Drug-eluting stents:capable of saving lives in dialysis patients?[J].JACC,2016,67:1470-1471.
[6]	NAKAMURA M,MURAMATSU T,YOKOI H,et al.Three-year follow-up outcomes of SES and PES in a randomized controlled study stratified by the presence of diabetes mellitus:J-DEsSERT trial[J].Int J Cardiol,2016,208:4-12.
[7]	KUFNER S,BYRNE R A,WAHA A D,et al.Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis:Results from the ISAR-DESIRE2 trial[J].Cardiovasc Revasc Med,2014,15:69-75.
[8]	STIERMAIER T,HEINZ A,SCHLOMA D,et al.Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus(LIPSIA Yukon trial)[J].Catheter Cardiovasc Interv,2014,83:418-424.
[9]	LEE S W,PARK S W,KIM Y H,et al.A randomized comparison of sirolimus-versus paclitaxel-eluting stent implantation in patients with diabetes mellitus:4-year clinical outcomes of DES-DIABETES(drug-eluting stent in patients with DIABETES mellitus)trial[J].JACC Cardiovasc Interv,2011,4:310-316.
[10]	COSGRAVE J,AGOSTONI P,LEI G,et al.Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions[J].Am J Cardiol,2005,96:1663-1668.
[11]	MAENG M,JENSEN L O,GALLOE A M,et al.Comparison of the sirolimus-eluting versus paclitaxeleluting coronary stent in patients with diabetes mellitus:The Diabetes and Drug-Eluting Stent(DiabeDES)Randomized Angiography Trial[J].Am J Cardiol,2009,103:345-349.
[12]	SUN-JOO J,DUK-WOO P,WON-JANG K,et al.Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients:Two-year subgroup analysis of the ZEST randomized trial.[J].Catheter Cardiovasc Interv,2012,81:1106-1114.
[13]	BRIGUORI C,AIROLDI F,VISCONTI G,et al.Novel approaches for preventing or limiting events in diabetic patients(Naples-diabetes)trial:a randomized comparison of 3drug-eluting stents in diabetic patients[J].Circ Cardiovasc Interv,2011,4:121-129.
[14]	KEREIAKES D J,CUTLIP D E,APPLEGATE R J,et al.Outcomes in diabetic and nondiabetic patients treated with everolimus-or paclitaxel-eluting stents[J].JACC,2010,56:2084-2089.
[15]	KANG W C,AHN T,LEE K,et al.Comparison of zotarolimus-elutingstents versus sirolimus-eluting stents versus paclitaxel-eluting stentsfor primary percutaneous coronary intervention in patients with ST elevation myocardial infarction:results from the Korean Multicentre Endeavor(KOMER)acute myocardial infarction(AMI)trial[J].Euro Interven,2011,7:936-943.
[16]	SUN J,MARX S O,CHEN H J,et al.Role for p27(Kip1)in vascular smooth muscle cell migration[J].Circulation,2001,103:2967-2972.
[17]	CHUNG E K,RHEE J A,BAIK Y H,et al.The effect of team-based learning in medical ethics education[J].Med Teach,2009,31:1013-1017.
[18]	NIENABER C A.Everolimus or paclitaxel stents in real life:go COMPARE[J].Lancet,2010,375:174-176.
[19]	LIU Y,LEI G,SONG Y,et al.Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus:A metaanalysis[J].Int J Cardiol,2015,184:680-691.